Carmelo Nucera

List of Publications by Year
in descending order

34 papers	4,468 citations	394421 19 h-index	377865 34 g-index
35 all docs	35 docs citations	35 times ranked	9647 citing authors

#	Article	IF	Citations
1	Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in <i>BRAF^{V600E}</i> Papillary Thyroid Carcinoma. Thyroid, 2021, 31, 1335-1358.	4.5	14
2	Role of Regulatory Non-Coding RNAs in Aggressive Thyroid Cancer: Prospective Applications of Neural Network Analysis. Molecules, 2021, 26, 3022.	3.8	5
3	Lenvatinib Targets PDGFR-Î² Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3569-3590.	3.6	6
4	Tumor Microenvironmentâ€"Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer. Advances in Experimental Medicine and Biology, 2021, 1329, 253-269.	1.6	11
5	Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy. Frontiers in Endocrinology, 2019, 10, 468.	3.5	5
6	Coding Molecular Determinants of Thyroid Cancer Development and Progression. Endocrinology and Metabolism Clinics of North America, 2019, 48, 37-59.	3.2	21
7	A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer. Oncotarget, 2019, 10, 686-687.	1.8	4
8	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFÎ²1 Axis. Clinical Cancer Research, 2018, 24, 6078-6097.	7.0	43
9	Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasisâ€"A case report. International Journal of Surgery Case Reports, 2017, 38, 180-184.	0.6	3
10	Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E. Oncotarget, 2017, 8, 84743-84760.	1.8	40
11	Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF. Cancer Letters, 2016, 380, 577-585.	7.2	11
12	Evolution of resistance to thyroid cancer therapy. Aging, 2016, 8, 1576-1577.	3.1	6
13	Effect of the micronutrient iodine in thyroid carcinoma angiogenesis. Aging, 2016, 8, 3180-3184.	3.1	8
14	Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. Endocrine-Related Cancer, 2015, 22, L23-L28.	3.1	5
15	Personalized Therapy in Patients With Anaplastic Thyroid Cancer: Targeting Genetic and Epigenetic Alterations. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 35-42.	3.6	60
16	Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. Discoveries, 2015, 3, e40.	2.3	5
17	Metastasis-associated <i>MCL1</i> and <i>P16</i> copy number alterations dictate resistance to vemurafenib in a <i>BRAFV600E</i> patient-derived papillary thyroid carcinoma preclinical model. Oncotarget, 2015, 6, 42445-42467.	1.8	40
18	Role of BRAFV600E in the First Preclinical Model of Multifocal Infiltrating Myopericytoma Development and Microenvironment. Journal of the National Cancer Institute, 2014, 106, .	6.3	31

#	Article	IF	Citations
19	Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAFV600E: New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Frontiers in Endocrinology, 2013, 4, 189.	3.5	22
20	Targeting Thyroid Cancer Microenvironment: Basic Research and Clinical Applications. Frontiers in Endocrinology, 2013, 4, 167.	3.5	11
21	Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer. Endocrinology, 2012, 153, 985-994.	2.8	57
22	FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocrine-Related Cancer, 2012, 19, 695-710.	3.1	36
23	SCFÎ²-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. Journal of Experimental Medicine, 2012, 209, 1289-1307.	8.5	85
24	Clinical Outcome, Role of BRAFV600E, and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?. Frontiers in Endocrinology, 2012, 3, 33.	3.5	15
25	Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer. Oncologist, 2011, 16, 296-309.	3.7	86
26	BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression. Cancer Research, 2011, 71, 2417-2422.	0.9	81
27	Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery, 2010, 148, 1154-1162.	1.9	31
28	Maternal thyroid hormones are transcriptionally active during embryoâ€“foetal development: results from a novel transgenic mouse model. Journal of Cellular and Molecular Medicine, 2010, 14, 2417-2435.	3.6	20
29	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	27.8	3,331
30	B-Raf^{V600E}and thrombospondin-1 promote thyroid cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10649-10654.	7.1	164
31	The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. Oncotarget, 2010, 1, 751-6.	1.8	24
32	A Novel Orthotopic Mouse Model of Human Anaplastic Thyroid Carcinoma. Thyroid, 2009, 19, 1077-1084.	4.5	73
33	<i>FOXA1</i> Is a Potential Oncogene in Anaplastic Thyroid Carcinoma. Clinical Cancer Research, 2009, 15, 3680-3689.	7.0	75
34	Role of B-RafV600E in differentiated thyroid cancer and preclinical validation of compounds against B-RafV600E. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 152-161.	7.4	39